Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ddMVAC in Locally Advanced Urothelial Carcinoma of Bladder
NCT04047693Phase 2Terminated
- Sponsor
- Pusan National University Hospital
- Start
- May 2019
- Primary completion
- Jan 2022
- Modality
- Targeted Liposomes, Orthosteric Ligands, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of methotrexate, vinblastine, pegylated liposomal doxorubicin, Cisplatin micelle injection (HA132), pegfilgrastim in urothelial carcinoma (UC), bladder cancer, sponsored by Pusan National University Hospital. Started May 2019; status: terminated.
02
Drugs
methotrexatevinblastinepegylated liposomal doxorubicinCisplatin micelle injection (HA132)pegfilgrastim
03
Conditions
urothelial carcinoma (UC)bladder cancer
Beyond the preview
Go deeper on NCT04047693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04047693.